Pearson, A. D., Barry, E., Mossé, Y. P., Ligas, F., Bird, N., de Rojas, T., Zimmerman, Z. F., Wilner, K., Woessmann, W., Weiner, S., Weigel, B., Venkatramani, R., Valteau, D., Trahair, T., Smith, M., Singh, S., Selvaggi, G., Scobie, N., Schleiermacher, G., Richardson, N., Park, J., Nysom, K., Norga, K., Merino, M., McDonough, J., Matloub, Y., Marshall, L. V., Lowe, E., Lesa, G., Irwin, M., Karres, D., Gajjar, A., Doz, F., Fox, E., DuBois, S. G., Donoghue, M., Casanova, M., Caron, H., Buenger, V., Bradford, D., Blanc, P., Barone, A., Reaman, G., & Vassal, G. (2021). second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European journal of cancer, 157, 198–213. http://access.bl.uk/ark:/81055/vdc_100144519838.0x000021